2022-04-01
ImmuneOnco Announced Appointment of Dr. Xiaodong Gan as Senior Vice President for Clinical trials
On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Frank Xiaodong Gan was appointed as the senior vice president of our Company in April 2022, and is responsible for clinical development of our Group in the United States.
View more